101 related articles for article (PubMed ID: 35179040)
1. Circulating Cystatin C Is an Independent Risk Marker for Cardiovascular Outcomes, Development of Renal Impairment, and Long-Term Mortality in Patients With Stable Coronary Heart Disease: The LIPID Study.
West M; Kirby A; Stewart RA; Blankenberg S; Sullivan D; White HD; Hunt D; Marschner I; Janus E; Kritharides L; Watts GF; Simes J; Tonkin AM;
J Am Heart Assoc; 2022 Mar; 11(5):e020745. PubMed ID: 35179040
[TBL] [Abstract][Full Text] [Related]
2. Cystatin C Is a Gender-Neutral Glomerular Filtration Rate Biomarker in Patients with Cirrhosis.
Mindikoglu AL; Opekun AR; Mitch WE; Magder LS; Christenson RH; Dowling TC; Weir MR; Seliger SL; Howell CD; Raufman JP; Rana A; Goss JA; Khaderi SA; Vierling JM
Dig Dis Sci; 2018 Mar; 63(3):665-675. PubMed ID: 29392554
[TBL] [Abstract][Full Text] [Related]
3. Non-invasive estimation of glomerular filtration rate (GFR). The Lund model: Simultaneous use of cystatin C- and creatinine-based GFR-prediction equations, clinical data and an internal quality check.
Grubb A
Scand J Clin Lab Invest; 2010 Apr; 70(2):65-70. PubMed ID: 20170415
[TBL] [Abstract][Full Text] [Related]
4. Cystatin C identifies patients with stable chronic heart failure at increased risk for adverse cardiovascular events.
Dupont M; Wu Y; Hazen SL; Tang WH
Circ Heart Fail; 2012 Sep; 5(5):602-9. PubMed ID: 22899766
[TBL] [Abstract][Full Text] [Related]
5. Cystatin C as a biomarker of chronic kidney disease: latest developments.
Benoit SW; Ciccia EA; Devarajan P
Expert Rev Mol Diagn; 2020 Oct; 20(10):1019-1026. PubMed ID: 32450046
[TBL] [Abstract][Full Text] [Related]
6. Prognostic Value of Isolated High Serum Cystatin C Levels Without Glomerular Filtration Rate Reduction.
Cancho B; Alvarez Lopez A; Valladares J; Rodriguez Sabillon JA; Lopez Gomez J; Robles NR
Med Clin (Barc); 2024 Jun; 162(11):511-515. PubMed ID: 38388320
[TBL] [Abstract][Full Text] [Related]
7. Brief Report: Tyrosine Kinase Inhibitors for Lung Cancers That Inhibit MATE-1 Can Lead to "False" Decreases in Renal Function.
Chen MF; Harada G; Liu D; DeMatteo R; Falcon C; Wilhelm C; Kris MG; Drilon A; Gutgarts V
J Thorac Oncol; 2024 Jan; 19(1):153-159. PubMed ID: 37748692
[TBL] [Abstract][Full Text] [Related]
8. The Value of a Cystatin C-based Estimated Glomerular Filtration Rate for Cardiovascular Assessment in a General Japanese Population: Results From the Iwate Tohoku Medical Megabank Project.
Osaki T; Satoh M; Tanaka F; Tanno K; Takahashi Y; Nasu T; Sakata K; Morino Y; Sobue K; Sasaki M
J Epidemiol; 2020 Jun; 30(6):260-267. PubMed ID: 31130557
[TBL] [Abstract][Full Text] [Related]
9. Cystatin C: a new renal marker and its potential use in small animal medicine.
Ghys L; Paepe D; Smets P; Lefebvre H; Delanghe J; Daminet S
J Vet Intern Med; 2014; 28(4):1152-64. PubMed ID: 24814357
[TBL] [Abstract][Full Text] [Related]
10. Cystatin C Predicts Incident Cardiovascular Disease in Twins.
Arpegård J; Magnusson PK; Chen X; Ridefelt P; Pedersen NL; De Faire U; Svensson P
J Am Heart Assoc; 2016 Jun; 5(6):. PubMed ID: 27353608
[TBL] [Abstract][Full Text] [Related]
11. Development and Evaluation of a Quantitative Fluorescent Lateral Flow Immunoassay for Cystatin-C, a Renal Dysfunction Biomarker.
Natarajan S; DeRosa MC; Shah MI; Jayaraj J
Sensors (Basel); 2021 May; 21(9):. PubMed ID: 34063596
[TBL] [Abstract][Full Text] [Related]
12. Cystatin C--a paradigm of evidence based laboratory medicine.
Chew JS; Saleem M; Florkowski CM; George PM
Clin Biochem Rev; 2008 May; 29(2):47-62. PubMed ID: 18787643
[TBL] [Abstract][Full Text] [Related]
13. Serum Cystatin C, a Sensitive Marker of Renal Function and Cardiovascular Disease, Decreases After Smoking Cessation.
Funamoto M; Shimizu K; Sunagawa Y; Katanasaka Y; Miyazaki Y; Komiyama M; Yamakage H; Satoh-Asahara N; Takahashi Y; Wada H; Hasegawa K; Morimoto T
Circ Rep; 2019 Nov; 1(12):623-627. PubMed ID: 33693109
[No Abstract] [Full Text] [Related]
14. [Not Available].
Comte D
Rev Med Suisse; 2024 Mar; 20(866):615. PubMed ID: 38506468
[No Abstract] [Full Text] [Related]
15. Multiplexed MRM-based proteomics for identification of circulating proteins as biomarkers of cardiovascular damage progression associated with diabetes mellitus.
Piarulli F; Banfi C; Ragazzi E; Gianazza E; Munno M; Carollo M; Traldi P; Lapolla A; Sartore G
Cardiovasc Diabetol; 2024 Jan; 23(1):36. PubMed ID: 38245742
[TBL] [Abstract][Full Text] [Related]
16. Targeting inflammation in atherosclerosis: overview, strategy and directions.
Waksman R; Merdler I; Case BC; Waksman O; Porto I
EuroIntervention; 2024 Jan; 20(1):32-44. PubMed ID: 38165117
[TBL] [Abstract][Full Text] [Related]
17. Joint Associations of Pregnancy Complications and Postpartum Maternal Renal Biomarkers With Severe Cardiovascular Morbidities: A US Racially and Ethnically Diverse Prospective Birth Cohort Study.
Hong X; Rosenberg AZ; Heymann J; Yoshida T; Waikar SS; Ilori TO; Wang G; Rebuck H; Pearson C; Wang MC; Winkler CA; Kopp JB; Wang X
J Am Heart Assoc; 2023 Nov; 12(22):e029311. PubMed ID: 37947096
[TBL] [Abstract][Full Text] [Related]
18. Predictive value of serum human epididymis protein 4 for heart failure in patients with chronic kidney disease.
Dong C; Feng S; Ma H; Lei Y; Guo L; Sun Z
Am J Transl Res; 2023; 15(9):5664-5673. PubMed ID: 37854237
[TBL] [Abstract][Full Text] [Related]
19. The potential of cystatin C as a predictive biomarker in pulmonary hypertension.
Duan A; Huang Z; Zhao Z; Zhao Q; Jin Q; Yan L; Zhang Y; Li X; Zhang S; Hu M; Gao L; An C; Luo Q; Liu Z
BMC Pulm Med; 2023 Aug; 23(1):311. PubMed ID: 37633906
[TBL] [Abstract][Full Text] [Related]
20. Antiretroviral Treatment-Induced Galectin-9 Might Impact HIV Viremia in Addition to Contributing to Inflammaging.
Shete A; Wagh V; Sawant J; Shidhaye P; Sane S; Rao A; Kulkarni S; Ghate M
Int J Mol Sci; 2023 Jul; 24(15):. PubMed ID: 37569647
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
